Sophia Kamran, MD, Massachusetts General Hospital, Boston, MA, gives an overview of the current research on trimodality therapy (TMT) for patients with muscle-invasive bladder cancer. Ongoing studies are investigating the development of a biomarker to determine response to TMT and enable personalised treatment. Furthermore, studies are investigating the use of additional therapies including immunotherapy and adaptive radiotherapy with TMT. This interview took place at the American Society for Radiation Oncology (ASTRO) 2022 Congress in San Antonio, Tx.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.